INPP FY Pre-tax Profit Down

By RTTNews Staff Writer ✉ | Published: 4/9/2020 2:40 AM ET

International Public Partnership (INPP.L) reported that its profit before tax for fiscal year 2019 declined to 137.8 million pounds from 138.1 million pounds in the prior year.

Profit for the year was 138.17 million pounds, compared to 138.37 million pounds in the previous year. Earnings per share from continuing operations was 9.17 pence down from 9.75 pence last year.

But, total income grew to 173.52 million pounds from 167.67 million pounds in the previous year.

The company reaffirmed that the operational performance of its investment portfolio continues as expected and there has been no material change since the Market Update issued on 26 March 2020.

The company reaffirmed its target dividend for 2020 of 7.36 pence per share and provide new guidance of 7.55 pence per share for 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In July 2020

New Drugs Approved In May

Biotech Stocks Facing FDA Decision In June 2020

Editors Pick

Cottage Town Bedroom Furniture Collection Recalled For Lead Concerns

Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard.

Sanofi, Regeneron Stop Kevzara COVID-19 Trial In U.S. After Failing To Meet Key Goals

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.

Moderna Reportedly Delays Phase 3 Trial Of COVID-19 Vaccine

Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...